A Product For Gaucher Disease And A Plant-Cell For Protein Production – Protalix Biotherapeutics Is On The Rise

Protalix has a unique plant-cell platform for therapeutic protein production and an approved product, Elelyso/Uplyso (taliglucerase alfa), for Gaucher disease. In the company’s pipeline is a chemically modified version of the recombinant alpha-Galactosidase-A protein for Fabry disease (Phase 1/2), an oral glucocerebrosidase (GCD) enzyme replacement therapy for Gaucher disease (Phase 1), an oral anti-TNF (tumor necrosis factor) fusion protein for autoimmune/inflammatory conditions (preclinical), and a human deoxyribonuclease I (DNase I) for cystic fibrosis (preclinical), and other enzyme replacement therapies in early research.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news